Healio (4/23, Gramigna) reported, “Benzoate treatment appeared to improve cognitive function among women with later-phase dementia,” investigators concluded after analyzing “data of 97 patients (64% women; mean age, 75.4 years) with behavioral and psychological symptoms who were included in a randomized, double-masked, placebo-controlled trial that took place across three major medical centers in Taiwan.” Trial participants “received six weeks of treatment with 250 mg to 1,500 mg per day of sodium benzoate (n = 49) or placebo (n = 48).” The findings were published online in JAMA Network Open. (SOURCE: APA Headlines)